Table 4.
Phase II Trial Patients Versus MSKCC Contemporary Patients Treated With GCa Alone
| Characteristic | GCa + B (n = 47) |
GCa Alone (n = 90) |
||||
|---|---|---|---|---|---|---|
| No. of Patients | % | 95% CI | No. of Patients | % | 95% CI | |
| Age, years | ||||||
| Median | 67 | 77 | ||||
| Range | 42-83 | 44-85 | ||||
| Sex | ||||||
| Male | 36 | 77 | 60 | 67 | ||
| Female | 11 | 23 | 30 | 33 | ||
| KPS | ||||||
| ≤ 70 | 6 | 13 | 21 | 23 | ||
| 80 | 22 | 47 | 46 | 51 | ||
| 90 | 19 | 40 | 23 | 26 | ||
| MSKCC risk group | ||||||
| 0 | 12 | 26 | 32 | 36 | ||
| 1 | 31 | 66 | 45 | 50 | ||
| 2 | 4 | 9 | 13 | 14 | ||
| Median OS, months | 13.9 | 11.9 to 18.1 | 10.3 | 8.2 to 14.5 | ||
Abbreviations: B, bevacizumab; GCa, gemcitabine and carboplatin; KPS, Karnofsky performance status; MSKCC, Memorial Sloan-Kettering Cancer Center; OS, overall survival.